bluebird bio acquires manufacturing facility in North Carolina
bluebird bio (BLUE) announced it has acquired a 125,000-square foot manufacturing facility in Durham, North Carolina. Once construction and validation is complete, the site will produce lentiviral vector for the company's gene and cell therapies, including: Lenti-D for the treatment of cerebral adrenoleukodystrophy; LentiGlobin for the treatment of transfusion-dependent beta-thalassemia and severe sickle cell disease; and bb2121 and bb21217 for the treatment of multiple myeloma. The company is making a significant investment in its manufacturing infrastructure as it advances multiple products into late-stage development and potential commercial launch. Expanding in-house expertise, creating an extensive manufacturing network, and increasing manufacturing capacity ensures that bluebird can deliver on the promise of these product candidates. In addition to the internal manufacturing capacity that this site will provide, bluebird bio also has now entered into multi-year agreements with three manufacturing partners in the United States and Europe: Brammer Bio, Novasep and MilliporeSigma, the Life Science business of Merck (MRK). Each of these partners is collaborating with bluebird bio on production of lentiviral vector across all programs.The initial North Carolina site build-out will allow for production of clinical and commercial supply of lentiviral vector, which is a critical component of the company's gene and cell therapies. The facility is large enough to accommodate significant potential future expansion, including the possibility of commercial drug product production.